NCT06475196View on ClinicalTrials.gov

Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC

Enrolling by invitationOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

June 20, 2024

Study Completion Date

June 20, 2025

Conditions
Resectable Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Sintilimab (PD-1 inhibitor)

to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.

Trial Locations (1)

710000

Tangdu Hospital of the Fourth Millitary Medical University, Xi'an

All Listed Sponsors
lead

Tang-Du Hospital

OTHER